
In a new study, researchers investigated the roles of Dicer in replication-associated DNA damage during development. The team chose a model of the developing cerebellum for the study.

In a new study, researchers investigated the roles of Dicer in replication-associated DNA damage during development. The team chose a model of the developing cerebellum for the study.

Neurosurgeons at UC San Diego Health are making headway in a study of minimally invasive laser treatment of brain tumors focused on improving quality of life for patients who have been diagnosed with glioblastoma.

Building on previous work showing increased NF-kB activity in lung cancers, one research team has recently published a study showing this activity is also enhanced in glioblastoma, one of the most lethal forms of human cancers.

A study analysis tackles the ethical debate surrounding the impact of the increasing requirement for research biopsies on the participation of patients with advanced non-small lung cancer in clinical trials.

Howard L. Kaufman, MD, FACS, associate director for clinical science and chief surgical officer at Rutgers Cancer Institute of New Jersey, will serve as editor-in-chief of The Journal of Targeted Therapies in Cancer and Targeted Therapies in Oncology.

Researchers have identified a potential new biomarker for non-small cell lung cancer (NSCLC), which may help increase the efficacy of an emerging vaccine based on the MUC-1 antigen.

As new information regarding the efficacy of targeted and immunotherapeutic approaches emerge, the standard of care for patients with melanoma becomes slightly more altered.

Patients who elect to undergo immediate surgery for low-risk thyroid-related microcarcinoma may be subjecting themselves to unnecessary risk, according to findings from a large study in Japan.

The presence or absence of certain serum-free fatty acids could be an excellent diagnostic tool to differentiate between patients with either benign thyroid diseases or thyroid cancer.

A new retrospective study claimed a rarity of cytogenetic and molecular monitoring exists among patients with chronic myelogenous leukemia (CML) treated in a community setting; however, one researcher is challenging that claim.

A comparison preclinical study pitting a sugary diet with one less sweet shows the former resulting in increased breast cancer tumor growth and metastasis.

Venetoclax has been granted priority review status by the FDA for use in adults with chronic lymphocytic leukemia (CLL) following at least 1 prior therapy. This patient population includes those with a 17p deletion (del[17p]), according to codevelopers of the BCL-2 inhibitor AbbVie and Genentech.

A new 26-gene-screening panel, dubbed myBRCA HiRisk, hitting the market in the first quarter of 2016 aims to advance the prevention of hereditary breast and ovarian cancer.

Despite the initial controversy caused over 6 years ago, the US Preventive Services Task Force (USPSTF) has released a final version of its guidelines that stick to its initial assessment.

Although FGFR pathway deregulation has been identified frequently in NSCLC, clinical activity of FGFR inhibitors has been considered disappointing and modest, at best, to date.

A current estimation shows that roughly 25% of metastatic castration-resistant prostate cancers (mCRPC) contain alterations in DNA repair genes. These would normally code for proteins to correct errors arising when cells duplicate their DNA before cell division.

Omid Hamid, MD, discusses the upcoming Annual International Symposium on Melanoma and Other Cutaneous Malignancies.

A gene associated with the suppression of tumor growth has been found to act in the opposite manner in some forms of colorectal cancer (CRC), according to researchers at the University of Missouri School of Medicine.

With an expanding treatment paradigm for patients with colorectal cancer (CRC) at their fingertips, oncologists are working out the best methods of use for their new armamentarium, says John L. Marshall, MD.

The use of computed-tomography (CT)-planned high-dose-rate (HDR) intracavitary brachytherapy (BT) demonstrated excellent local control (LC) and survival for patients with stage I/II cervical carcinoma.

The programmed cell death 1 (PD-1) and PD-1 ligand (PD-L1) inhibitors "are going to disrupt the current treatment paradigm and will likely be the backbone of combination therapy," said Hans J. Hammers, MD, PhD.

An upcoming phase I trial seeks to evaluate a combination of interferon gamma-1b (ACTIMMUNE) and nivolumab (Opdivo) in patients with advanced solid tumors who have progressed on at least one prior systemic therapy.

The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

An orphan drug designation has been granted to the multi-epitope folate receptor alpha (FRα) vaccine TPIV 200 as a treatment for patients with ovarian cancer by the FDA.

The FDA has received a new drug application for cabozantinib (Cometriq) as a treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.

A new study has analyzed intratumoral heterogeneity (ITH) in 12 cancer types and found a "tolerable" level of genomic instability, independent of cancer type, beyond which a cancer may become less aggressive.

A correlation was drawn between adjuvant hormone therapy (AHT) and a 37% reduction in the risk of death in women with epithelial ovarian cancer, according to results of a 24-year study.

A new method of screening utilizing CA-125 and a risk assessment algorithm could drop risk of mortality from ovarian cancer in certain women, according to findings from the UK Collaborative Trial of Ovarian Cancer Screening.

Afatinib utilized as a frontline treatment reduced risk of progression or death by 27%, as compared to gefitinib in patients with EGFR-mutant non-small cell lung cancer. according to a recent phase IIb trial.

The FDA has assigned a breakthrough therapy status to the third-generation EGFR TKI BI-1482694 as a possible treatment for patients with T790M-positive non